Ozanimod-Associated Iatrogenic Kaposi Sarcoma in a Patient With Ulcerative Colitis. Issue 2 (10th February 2023)

• Record Type: Journal Article
• Authors: Sandlow, Sarah; Rai, Puja; Shum, Ann; Chen, Hannah; Arnold, Jeffrey; Jangi, Sushrut
• Is Part Of: ACG Case Reports Journal. Volume 10:Issue 2(2023)
• Page Start: e00929
• Publication Date: 2023-02-10
• DOI: 10.14309/crj.0000000000000929
• Languages: English
• ISSNs: 2326-3253

Abstract

ABSTRACT: Ozanimod is an oral sphingosine-1-phosphate receptor modulator. Although it can be an effective drug for the induction and maintenance of remission in patients with moderately to severely active ulcerative colitis, there have been a few reported cases of various malignancies after exposure to this small molecule. We describe a unique case of biopsy-proven Kaposi sarcoma of the skin and colon in a patient with biologic-resistant ulcerative colitis after treatment with ozanimod for 2 months. Given the potential risk of malignancy associated with this agent, physicians should be aware of this rare adverse event.